Product Pathways - Tyrosine Kinase / Adaptors
Met (L41G3) Mouse mAb (Biotinylated) #5086
PhosphoSitePlus® protein, site, and accession data: Met
| Applications | Reactivity | Sensitivity | MW (kDa) | Isotype |
|---|---|---|---|---|
| W | H Mk | Endogenous | 145 | Mouse IgG1 |
Applications Key:
W=Western Blotting
Reactivity Key:
H=Human
Mk=Monkey
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.
Protocols
- 5086:
- Western Blotting
Specificity / Sensitivity
Met (L41G3) Mouse mAb (Biotinylated) detects endogenous levels of total Met protein. It does not cross-react with related proteins.
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to the carboxy terminus of human Met.
Description
This Cell Signaling Technology antibody is conjugated to biotin under optimal conditions. The biotinylated antibody is expected to exhibit the same species cross-reactivity as the unconjugated Met (L41G3) Mouse mAb #3148.
Background
Met, a high affinity tyrosine kinase receptor for hepatocyte growth factor (HGF, also known as scatter factor) is a disulfide-linked heterodimer made of 45 kDa α- and 145 kDa β-subunits (1,2). The α-subunit and the amino-terminal region of the β-subunit form the extracellular domain. The remainder of the β-chain spans the plasma membrane and contains a cytoplasmic region with tyrosine kinase activity. Interaction of Met with HGF results in autophosphorylation at multiple tyrosines, which recruit several downstream signaling components, including Gab1, c-Cbl, and PI3 kinase (3). These fundamental events are important for all of the biological functions involving Met kinase activity. The addition of a phosphate at cytoplasmic Tyr1003 is essential for Met protein ubiquitination and degradation (4). Phosphorylation at Tyr1234/1235 in the Met kinase domain is critical for kinase activation. Phosphorylation at Tyr1349 in the Met cytoplasmic domain provides a direct binding site for Gab1 (5). Research studies have shown that altered Met levels and/or tyrosine kinase activities are found in several types of tumors, including renal, colon, and breast. Thus, investigators have concluded that Met is an attractive potential cancer therapeutic and diagnostic target (6,7).
- Cooper, C.S. et al. (1984) Nature 311, 29-33.
- Bottaro, D.P. et al. (1991) Science 251, 802-4.
- Bardelli, A. et al. (1997) Oncogene 15, 3103-11.
- Taher, T.E. et al. (2002) J Immunol 169, 3793-800.
- Schaeper, U. et al. (2000) J Cell Biol 149, 1419-32.
- Eder, J.P. et al. (2009) Clin Cancer Res 15, 2207-14.
- Sattler, M. and Salgia, R. (2009) Update Cancer Ther 3, 109-118.
Application References
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
Companion Products
- 4560 Met Antibody
- 3999 Streptavidin-HRP
- 3127 Met (25H2) Mouse mAb
- 3121 Phospho-Met (Tyr1349) Antibody
- 3148 Met (L41G3) Mouse mAb
- 3077 Phospho-Met (Tyr1234/1235) (D26) XP® Rabbit mAb
- 4033 Phospho-Met (Tyr1234/1235) (D26) XP® Rabbit mAb (Biotinylated)
For Research Use Only. Not For Use In Diagnostic Procedures.